MedTrace Logo

Effect of Intravitreal Ranibizumab Injection With Retinal Vein Occlusion (RVO)

NCT00942864 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2016-09-29

No results posted yet for this study

Summary

The purpose of this study is to evaluate the effects of intravitreal Lucentis® (Ranibizumab) and investigate the anatomical and functional improvement following this treatment in patients with macular edema due to retinal vein occlusion (RVO).

Conditions

  • Macular Edema
  • Retinal Vein Occlusion

Interventions

DRUG

ranibizumab

ranibizumab 0.5mg (0.05ml volume), intravitreal injection first 3 injection every 4 weeks additional injection (optional) according to the judgement of doctor

Sponsors & Collaborators

  • Novartis Korea Ltd.

    lead INDUSTRY

Principal Investigators

  • Seung-Young Yu · Dept. ophthalmology, Kyunghee medical center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2009-12-31
Completion
2009-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00942864 on ClinicalTrials.gov